AUTHORS: Amy Boyers, Solen Monteil, Mariam Bibi OBJECTIVES Early Access Programmes (EAPs) prov...
Read moreThe European Commission's 4th implementing act outlines how health tech developers can obtain early ...
Read moreWe examine how real-world evidence strategies help address uncertainties in rare disease treatments ...
Read moreAchieving HTA approval for orphan drugs requires strategic planning, early engagement, strong eviden...
Read moreWe're thrilled to announce our participation at World Orphan Drug Congress Europe 2024 in Barcelona ...
Read moreWe're delighted to announce our participation at ISPOR Europe 2024 in Barcelona this November. We'll...
Read moreWe explore whether pharma and biotech manufacturers are ready for the new EU HTA process and what op...
Read moreWe examine whether the joint clinical assessment will expedite patient access and influence value pe...
Read moreOur latest article discusses key strategies for pharma manufacturers' commercial readiness for EU HT...
Read moreKey findings from the ABPI's latest report highlight challenges and opportunities in NICE's health t...
Read more